⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Figure S1 from Development and Application of Radioactive Ligands Targeting Fibroblasts with Albumin-Binding Sites

Tongtong Wu Zhicong Yang Sufan Tang Hongmei Yuan Yang Liu Haiyang Li Nan Liu Zhanwen Huang Yue Chen Zhijun Zhou

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: The ESI-MS spectrum reveals key properties of DOTA-LP for targeting fibroblasts.
KEY EVIDENCE: The HPLC analysis confirms the purity and stability of DOTA-LP in the ligand formulation.
APPROACH: Analytical methods include ESI-MS and HPLC for evaluating the performance of radioactive ligands.
SIGNIFICANCE: Insights from the spectrum and analysis can enhance ligand design for targeted therapeutic applications.

Implication

Analytical results demonstrate DOTA-LP spectrum and HPLC profiles in fibroblast targeting, suggesting effective ligand design.

Abstract

Figure S1.ESI-MS spectrum and HPLC analysis of DOTA-LP. See main text for corresponding analytical conditions.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d02ae https://doi.org/10.1158/1535-7163.29759974

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from Development and Application of Radioactive Ligands Targeting Fibroblasts with Albumin-Binding Sites2025
2Figure S3 from Development and Application of Radioactive Ligands Targeting Fibroblasts with Albumin-Binding Sites2025
3Figure S4 from Development and Application of Radioactive Ligands Targeting Fibroblasts with Albumin-Binding Sites2025
4Figure S7 from Development and Application of Radioactive Ligands Targeting Fibroblasts with Albumin-Binding Sites2025
5Figure S8 from Development and Application of Radioactive Ligands Targeting Fibroblasts with Albumin-Binding Sites2025

Figure S5 from Development and Application of Radioactive Ligands Targeting Fibroblasts with Albumin-Binding Sites2025
Figure S6 from Development and Application of Radioactive Ligands Targeting Fibroblasts with Albumin-Binding Sites2025
Figure S11 from Development and Application of Radioactive Ligands Targeting Fibroblasts with Albumin-Binding Sites2025